What Is Ionis Pharmaceuticals, Inc. (IONS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Ionis Pharmaceuticals, Inc.'s intrinsic value is estimated at $20.65, suggesting the stock is overvalued at its current price of $54.73. With 11 out of 12 models flagging downside (-62.3% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +32.4% (fair value: $72.49), while Sentiment SOTP is the most conservative at -97.8% ($1.22). The spread between these extremes — +130.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About IONS?
12 of 13 models are currently active for IONS. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates IONS's intrinsic value at $25.27, implying -53.8% downside from the current price. See which stocks rank higher →
How Does IONS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, IONS ranks #370 by Quality of Company score. CirclFi's QOC score of 3.5/10 evaluates 32 fundamental signals. A score of 3.5 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Ionis Pharmaceuticals, Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating IONS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is IONS a Value Trap?
CirclFi's Value Trap algorithm assigns IONS a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Ionis Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Ionis Pharmaceuticals, Inc.'s fundamental quality profile registers 3.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +130.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IONS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IONS's 12 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad